Update in the management of chronic lymphocytic leukemia

od Maddocks, Kami J, Lin, Thomas S
Izdano 2009

What's new in the management of chronic lymphocytic leukemia? 2008 ASH Review (New York Medical College, January 31, 2009)

od Maddocks, Kami J, Lin, Thomas S
Izdano 2009

Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions

od Bond, David A, Martin, Peter, Maddocks, Kami J
izdano v J Clin Med (2021)

Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

od Goyal, Neha G, Maddocks, Kami J, Johnson, Amy J, Byrd, John C, Westbrook, Travis D, Andersen, Barbara L
izdano v Ann Behav Med (2018)

A phase 2 trial of alisertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

od Cohen, Jonathon B., Maddocks, Kami J., Huang, Ying, Christian, Beth A., Jaglowski, Samantha M., Flowers, Christopher R., Blum, Kristie A.
izdano v Leuk Lymphoma (2017)

Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal’s Self-regulatory Model

od Westbrook, Travis D, Morrison, Eleshia J, Maddocks, Kami J, Awan, Farrukh T, Jones, Jeffrey A, Woyach, Jennifer A, Johnson, Amy J, Byrd, John C, Andersen, Barbara L
izdano v Ann Behav Med (2018)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia

od Heerema, Nyla A., Muthusamy, Natarajan, Zhao, Qiuhong, Ruppert, Amy S., Breidenbach, Heather, Andritsos, Leslie A., Grever, Michael R., Maddocks, Kami J., Woyach, Jennifer, Awan, Farrukh, Long, Meixiao, Gordon, Amber, Coombes, Caitlin, Byrd, John C.
izdano v Haematologica (2020)

Incidence and Description of Autoimmune Cytopenias During Treatment with Ibrutinib for Chronic Lymphocytic Leukemia Autoimmune Cytopenias During Ibrutinib Treatment

od Rogers, Kerry A., Ruppert, Amy S., Bingman, Anissa, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie A., Flynn, Joseph M., Jaglowski, Samantha M., Lozanski, Gerard, Maddocks, Kami J., Byrd, John C., Woyach, Jennifer A., Jones, Jeffrey A.
izdano v Leukemia (2015)

17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

od Hertlein, Erin, Wagner, Amy J., Jones, Jeffrey, Lin, Thomas S., Maddocks, Kami J., Towns, William H., Goettl, Virginia M., Zhang, Xiaoli, Jarjoura, David, Raymond, Chelsey A., West, Derek A., Croce, Carlo M., Byrd, John C., Johnson, Amy J.
Izdano 2010

Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia

od Chen, Timothy L., Gupta, Nikhil, Lehman, Amy, Ruppert, Amy S., Yu, Lianbo, Oakes, Christopher C., Claus, Rainer, Plass, Christoph, Maddocks, Kami J., Andritsos, Leslie, Jones, Jeffery A., Lucas, David M., Johnson, Amy J., Byrd, John C., Hertlein, Erin
izdano v Oncotarget (2016)

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy

od Landsburg, Daniel J., Hughes, Mitchell E., Koike, Alexa, Bond, David, Maddocks, Kami J., Guo, Ling, Winter, Allison M., Hill, Brian T., Ondrejka, Sarah L., Hsi, Eric D., Nasta, Sunita D., Svoboda, Jakub, Schuster, Stephen J., Bogusz, Agata M.
izdano v Blood Adv (2019)

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

od Bond, David A, Huang, Ying, Fisher, James L, Ruppert, Amy S, Owen, Dwight H, Bertino, Erin M, Rogers, Kerry A, Bhat, Seema A, Grever, Michael R, Jaglowski, Samantha M, Maddocks, Kami J, Byrd, John C, Woyach, Jennifer A
izdano v Leukemia (2020)

Phase I Dose Escalation Trial of the Novel Proteasome Inhibitor Carfilzomib in Patients with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

od Awan, Farrukh T., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami J., Sass, Ellen J., Lucas, Margaret S., Chase, Weihong, Waymer, Sharon, Ling, Yonghua, Jiang, Yao, Phelps, Mitch A., Byrd, John C., Lucas, David M., Woyach, Jennifer A.
izdano v Leuk Lymphoma (2015)

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

od Rogers, Kerry A., Huang, Ying, Ruppert, Amy S., Awan, Farrukh T., Heerema, Nyla A., Hoffman, Corinne, Lozanski, Gerard, Maddocks, Kami J., Moran, Mollie E., Reid, Mark A., Lucas, Margaret, Woyach, Jennifer A., Whitlow, W. Thomas, Jones, Jeffrey A., Byrd, John C.
izdano v Blood (2018)

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

od Beckwith, Kyle A., Frissora, Frank W., Stefanovski, Matthew R., Towns, William H., Cheney, Carolyn, Mo, Xiaokui, Deckert, Jutta, Croce, Carlo M., Flynn, Joseph M., Andritsos, Leslie A., Jones, Jeffrey A., Maddocks, Kami J., Lozanski, Gerard, Byrd, John C., Muthusamy, Natarajan
Izdano 2014

Complete Response to Induction Therapy in Patients With Myc-Positive and Double-Hit Non-Hodgkin Lymphoma Is Associated With Prolonged Progression-Free Survival

od Cohen, Jonathon B., Geyer, Susan M., Lozanski, Gerard, Zhao, Weiqiang, Heerema, Nyla A., Hall, Nathan C., Nagar, Veena A., Hemminger, Jessica A., Jones, Jeffrey A., Porcu, Pierluigi, Christian, Beth A., Baiocchi, Robert A., Maddocks, Kami J., Flynn, Joseph M., Devine, Steven M., Blum, Kristie A.
izdano v Cancer (2014)

Selinexor suppresses Downstream Effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

od Zhong, Yiming, El-Gamal, Dalia, Dubovsky, Jason A., Beckwith, Kyle A., Harrington, Bonnie K., Williams, Katie E., Goettl, Virginia M., Jha, Shruti, Mo, Xiaokui, Jones, Jeffrey A., Flynn, Joseph M., Maddocks, Kami J., Andritsos, Leslie A., McCauley, Dilara, Shacham, Sharon, Kauffman, Michael, Byrd, John C., Lapalombella, Rosa
Izdano 2014

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

od Rogers, Kerry A., Huang, Ying, Ruppert, Amy S., Abruzzo, Lynne V., Andersen, Barbara L., Awan, Farrukh T., Bhat, Seema A., Dean, Allison, Lucas, Margaret, Banks, Christin, Grantier, Cara, Heerema, Nyla A., Lozanski, Gerard, Maddocks, Kami J., Valentine, Thomas R., Weiss, David M., Jones, Jeffrey A., Woyach, Jennifer A., Byrd, John C.
izdano v J Clin Oncol (2020)

Ibrutinib treatment improves T cell number and function in CLL patients

od Long, Meixiao, Beckwith, Kyle, Do, Priscilla, Mundy, Bethany L., Gordon, Amber, Lehman, Amy M., Maddocks, Kami J., Cheney, Carolyn, Jones, Jeffrey A., Flynn, Joseph M., Andritsos, Leslie A., Awan, Farrukh, Fraietta, Joseph A., June, Carl H., Maus, Marcela V., Woyach, Jennifer A., Caligiuri, Michael A., Johnson, Amy J., Muthusamy, Natarajan, Byrd, John C.
izdano v J Clin Invest (2017)

Etiology of Ibrutinib Discontinuation and Outcomes in Chronic Lymphocytic Leukemia Patients

od Maddocks, Kami J., Ruppert, Amy S., Lozanski, Gerard, Heerema, Nyla A., Zhao, Weiqiang, Abruzzo, Lynne, Lozanski, Arletta, Davis, Melanie, Gordon, Amber, Smith, Lisa L., Mantel, Rose, Jones, Jeffrey A., Flynn, Joseph M., Jaglowski, Samantha M., Andritsos, Leslie A., Awan, Farrukh, Blum, Kristie A., Grever, Michael R., Johnson, Amy J., Byrd, John C., Woyach, Jennifer A.
izdano v JAMA Oncol (2015)